Sanofi Exceeds Q1 Expectations Driven by Dupixent Growth

Sanofi (SNY) has delivered a robust first-quarter performance, reporting double-digit growth in both sales and business earnings that beat market consensus. The results underscore the company's ability to scale its core offerings amidst a competitive pharmaceutical landscape. The results highlight the continued commercial strength of Dupixent, which remains a primary driver of the company's top-line growth. By leveraging this strength, Sanofi has been able to offset other operational pressures and maintain a positive trajectory for the fiscal year. Financial highlights for the quarter include adjusted earnings per share (EPS) of €1.88 ($2.20). This figure represents a 14.0% increase when measured at constant exchange rates, and a 5.0% increase at actual exchange rates, both of which outperformed analyst expectations. Following the strong start to the year, Sanofi has reaffirmed its full-year guidance. This confirmation suggests management's confidence in the company's current pipeline and its ability to meet annual targets despite currency fluctuations and global market volatility.